Monitor upcoming clinical data readouts in 2026 as key catalysts; watch cash runway and potential need for future financing if development timelines extend.
Price Chart
Executive Summary
NextCure provided a business update and reported full-year 2025 financial results, highlighting anticipated clinical data readouts for its SIM0505 and LNCB74 ADC programs in 2026. The company expects to present Phase 1 dose escalation data for SIM0505 in Q2 2026 and initiate a dose optimization study in ovarian cancer, while continuing enrollment in the LNCB74 trial. Cash resources of $41.8 million are expected to fund operations into early 2027.
Key Financial Metrics
Key Facts
- Phase 1 dose escalation data for SIM0505 expected in Q2 2026
- Dose optimization study for SIM0505 in platinum-resistant ovarian cancer to begin in Q2 2026
- LNCB74 Phase 1 trial update planned for second half of 2026
- Cash, cash equivalents, and marketable securities were $41.8 million as of December 31, 2025
- Net loss was $55.8 million for full year 2025, flat vs. $55.7 million in 2024
- Research and development expenses increased to $44.9 million from $41.5 million in 2024
- General and administrative expenses decreased to $12.7 million from $15.7 million in 2024
- Current cash expected to fund operations into first half of 2027
Financial Impact
Cash burn of $26.8 million in 2025; R&D up $3.4 million due to $18.5M in SIM0505 license fees; G&A down $3.0M
Risk Factors
- Clinical trial results may not meet expectations, particularly given early-phase stage
- Cash runway extends only to mid-2027; future equity financing could lead to dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250665 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | SC 13G | $5.44 | awaiting T+60 | — | $5.22 (−3.95%) |
Sep 25, 2026 4w ago | 425 | $5.08 | awaiting T+60 | — | $5.22 (+2.85%) |
Sep 25, 2026 4w ago | 8-K | $5.08 | awaiting T+60 | — | $5.22 (+2.85%) |
Aug 10, 2026 11w ago | 425 | $6.73 | awaiting T+60 | — | $5.22 (+22.36%) |
Aug 4, 2026 11w ago | 425 | $5.78 | awaiting T+60 | — | $5.22 (−9.60%) |
Aug 3, 2026 12w ago | Insider Buy | $5.78 | awaiting T+60 | — | $5.22 (−9.60%) |
Jul 29, 2026 12w ago | Insider Buy | $5.03 $4.98 | ▼ −0.99% | ▼ −3.46% | $5.22 (+3.88%) |
Jul 14, 2026 14w ago | 425 / 8-K | $6.58 $6.56 | ▼ −0.30% | ▼ −3.68% | $5.22 (−20.59%) |
Jul 14, 2026 14w ago | 8-K | $6.58 $6.56 | ▲ +0.30% | ▲ +3.68% | $5.22 (+20.59%) |
Jun 1, 2026 21w ago | 8-K | $3.38 $5.91 | ▲ +74.85% | ▲ +73.62% | $5.22 (+54.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers